Cardiovascular Systems, Inc. ( CSII Quick Quote CSII - Free Report) recently announced the treatment of the first U.S. patient with its WIRION Embolic Protection System (EPS). Notably, the device offers an efficient approach for lower extremity embolic protection.
In August 2019, Cardiovascular Systems acquired the WIRION Embolic Protection System and related assets from Gardia Medical Ltd., a wholly-owned Israeli subsidiary of Allium Medical Solutions Ltd.
The recent development is a major breakthrough in the company’s mission to support a comprehensive portfolio of differentiated products intended to save limbs and improve outcomes for patients undergoing complex peripheral interventions.
WIRION at a Glance
WIRION is a distal embolic protection filter used to capture thrombus and debris that can be connected with all types of peripheral vascular intervention procedures, including atherectomy.
More in the News
Lawrence Garcia, MD, from St. Elizabeth’s Medical Center in Boston, MA, and Dr. Shammas from Unity Point Health-Trinity Bettendorf in Davenport, Iowa, participated as investigators in the WIRION EPS in the Lower Extremities Arteries (WISE LE) study. Notably, WISE LE was a multicenter study performed in the United States and Germany, incorporating all commercially-available atherectomy systems.
Per personnel associated with the treatment, WIRION verified a major adverse event (MAE) rate of 1.9%, lower than the earlier reported rates for other lower extremity embolic protection filters. Notably, no clinically considerable distal embolization was observed when treated with WIRION.
Per Dr. Shammas, WIRION’s delivery and retrieval are easy with a minimal learning curve. Moreover, debris capture is very efficient, making WIRION remarkably appropriate for use with any atherectomy device.
Industry Prospects Per a report by Grand View Research, the global embolic protection devices market size was valued at $820.2 million in 2017 and is expected to see a CAGR of 8.4% by 2026. Rising cases of cardiovascular, peripheral, and neurovascular surgeries and heavy investments in R&D of embolic devices are the key catalysts for the market. Recent Developments
In February 2021, Cardiovascular Systems announced the treatment of the first patient in Europe with its Diamondback 360 Coronary Orbital Atherectomy System (OAS). Notably, the use of Diamondback 360 Coronary OAS streamlines the treatment with a unique mechanism to successfully modify severe calcium and optimize stent performance.
During the same month, Cardiovascular Systems collaborated with Chansu Vascular Technologies, LLC to develop novel peripheral and coronary everolimus drug-coated balloons (DCBs). The collaboration will enable Cardiovascular Systems to develop a new class of DCBs that will enhance patient outcome.
Over the past six months, shares of the company have gained 21.5% compared with the
industry’s 11.1% rally. Zacks Rank and Key Picks
Currently, Cardiovascular Systems carries a Zacks Rank #3 (Hold).
A few better-ranked stocks from the broader medical space are
Envista Holdings Corporation ( NVST Quick Quote NVST - Free Report) , Meridian Bioscience Inc. ( VIVO Quick Quote VIVO - Free Report) and Owens & Minor, Inc. ( OMI Quick Quote OMI - Free Report) , each sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Envista’s long-term earnings growth rate is estimated at 24%.
Meridian Bioscience’s long-term earnings growth rate is projected at 61%.
Owens & Minor’s long-term earnings growth rate is estimated at 49%.
Zacks Top 10 Stocks for 2021
In addition to the stocks discussed above, would you like to know about our 10 best buy-and-hold tickers for the entirety of 2021?
Last year's 2020 Zacks Top 10 Stocks portfolio returned gains as high as +386.8%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Access Zacks Top 10 Stocks for 2021 today >>